Roche’s Avastin approved in Europe for breast cancer

Categories: Breast Cancer

Swiss drugmaker Roche said on Thursday that Avastin had been approved in Europe for the treatment of women with metastatic breast cancer.

The European Commission had approved Avastin for the first line treatment of women with metastatic breast cancer in combination with paclitaxel, Roche said in a statement.

You Might Like:
  • High-dose chemo doesn’t improve survival in metastatic breast cancer
  • Comorbidity reduces benefits of androgen suppression in prostate cancer
  • Statins don’t appear to be linked with breast cancer risk
  • Soft-tissue sarcoma outcomes vary widely by race, ethnicity
  • Even small copay deters mammogram use: U.S. study
  • Effective prostate cancer screening requires digital rectal exam
  • Clinical trial access more limited for teen cancer patients
  • MicroRNA signatures linked with AML prognosis, cytogenetics
  • Stop-and-go oxaliplatin effective in elderly colon cancer patients
  • In vitro fertilization safe in women treated for endometrial carcinoma
  • High-dose methotrexate effective treatment for primary CNS lymphoma
  • Docetaxel every three weeks best for certain metastatic prostate cancers
  • Chewing gum after cystectomy stimulates return of bowel motility
  • Surgeon factors affect receipt of radiotherapy for breast cancer
  • Multimodal treatment may help in invasive bladder cancer
    •

    Leave a Reply

    «
    »